Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-... (abetes. Itis used with metformin a sulfo...)

Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study

Date:10/31/2007

abetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used with a medicine that contains a sulfonylurea, low blood sugar (hypoglycemia) is a possible side effect. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea is most common when first starting BYETTA, but decreases over time in most patients.

If patients experience the following severe and persistent symptoms (alone or in combination): abdominal pain, nausea, vomiting, or diarrhea, they should talk to their healthcare provider because these symptoms could be signs of serious medical conditions. BYETTA may reduce appetite, the amount of food eaten, and body weight. No changes in dose are needed for these side effects. These are not all the side effects with BYETTA. A health care provider should be consulted about any side effect that is bothersome or does not go away.

For complete safety profile and other important prescribing considerations, visit http://www.BYETTA.com.

About Amylin, Lilly, and Alkermes

Amylin, Lilly, and Alkermes are working together to develop exenatide long-acting release injection, a subcutaneous injection of exenatide for the treatment of type 2 diabetes based on Alkermes' proprietary injectable long- acting release technology. Once-weekly exenatide has not been approved by the FDA for marketing in the United States or by regulatory agencies elsewhere in the world.

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives throu
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Diabetes Drug, Exenatide, Good For Blood Sugar Levels and Weight Loss
2. Osaka Medical Center study showed 70% of smokers couldn’t qui
3. Women Taking Oestrogen Therapy Showed Reduced Coronary Artery Calcification
4. Link Between Vietnam Service And Prostate Cancer Is Statistically Insignificant
5. Biomarkers Predicting Mortality Found Using Statistical Technique
6. Manmohan Calls for Statistical Reforms in Healthcare and Education
7. Treatment For Sleep Apnea Found To Lower Blood Glucose Levels
8. More soy benefits on blood glucose levels, and cholesterol
9. Lower risk of cardiovascular disease from tight glucose control
10. Glucose may support in Cardiac Arrest
11. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions

Post Your Comments:

Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-...(abetes. Itis used with metformin a sulfo...),Health